Table 3.
CRT response—echocardiographic and clinical measures at baseline and 6‐month follow‐up
| Variable | Baseline | 6‐Month follow‐up | p Value |
|---|---|---|---|
| LVEDV (ml) | 200.8 ± 75.8 | 178.0 ± 63.2 | 0.028 |
| LVESV (ml) | 133.8 ± 67.7 | 103.5 ± 53.9 | 0.003 |
| LVEF (%) | 36.2 ± 9.4 | 44.2 ± 11.2 | 0.038 |
| Paced QRS duration (ms)a | 154 ± 30 | 134 ± 21 | 0.016 |
| NYHA functional class | 2.1 ± 0.6 | 1.5 ± 0.7 | 0.031 |
| MLWHFQ score | 30.9 ± 23.6 | 27.3 ± 24.2 | 0.266 |
| 6MWT distance (m) | 341.8 ± 124.5 | 383.8 ± 138.1 | 0.178 |
| NT‐proBNP (pg/ml) | 1161.6 ± 903.9 | 1163.4 ± 1435.9 | 0.997 |
Note: All values are presented as mean ± SD. Absolute and percentage change values are the difference between values obtained from baseline pre‐assessment visit and 6‐month follow‐up.
Abbreviations: 6MWT, 6‐min walk test; CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; LVESV, left ventricular end‐systolic volume; MLWHFQ, Minnesota living with heart failure questionnaire; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.
a
QRS duration reflects the change in QRS duration from baseline to CRT at 6‐month follow‐up.